We've updated our Privacy Statement. Before you continue, please read our new Privacy Statement and familiarize yourself with the terms.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jeffrey Morton Ph.D
Hasty Provisional Costs Millions in Lost Revenue: Lessons from Enanta v. Pfizer
We've updated our Privacy Statement. Before you continue, please read our new Privacy Statement and familiarize yourself with the terms.
Federal Circuit’s Holding on Patent Eligibility for Engineered Host Cells Dovetails With PERA
U.S. Supreme Court opinions in Mayo Collaborative Services v. Prometheus Laboratories, Inc.1, Association for Molecular Pathology v. Myriad Genetics, Inc.2 and Alice Corporation Pty. Ltd. V. CLS Bank International et al.3, have left the Court of Appeals for the Federal Circuit grappling with the metes and bounds of patent subject matter eligibility, including the eligibility of nucleic acid sequences.
Federal Circuit Provides Guidance on Patentability of Recombinant Host Cells | JD Supra
On Feb. 20, 2026, the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) issued a thoughtful analysis of biotechnology subject-matter eligibility in REGENXBIO, Inc. v. Sarepta Therapeutics, Inc., No. 24-01408 (Fed. Cir. 2026).
Strategies to Consider with USPTO's New Fast-Track Examination Pilot Program | JD Supra
On Oct. 27, 2025, the U.S. Patent and Trademark Office (USPTO) announced it is offering a Streamlined Claim Set Pilot Program in an effort to further accelerate examination of currently pending applications with a limited number of claims. This Pilot Program supplements the Track One program, which remains in place. To qualify, a patent applicant must file a timely petition to make special under this new Pilot Program.
Life Sciences Due Diligence and the Interplay with Recent Prosecution Timing Changes at the USPTO | JD Supra
Most life sciences transactions result in intellectual property (IP) due diligence being carried out on underlying IP assets that are often central to the transaction. Typically, this includes a focus on patent due diligence to determine whether key patent assets are valid and enforceable. For many life sciences companies, and particularly for early-stage companies, patent prosecution is proceeding at the same time as active due diligence.
Morton in Daily Journal on AI Meets the Life Sciences
Haynes and Boone, LLP Partner Jeff Morton authored an article for Daily Journal after recent developments in artificial intelligence, where the new technology is revolutionizing life sciences, predicting protein structures, diagnosing conditions, and analyzing genetic predispositions. However, patent law challenges like inventorship and eligibility need attention. Read an excerpt below. Artificial intelligence (AI) continues to play an increasingly prominent role in life science-related inventions.
Morton and Wolfson in Westlaw Today: Patent Enablement Following 'Amgen v. Sanofi'
Haynes and Boone, LLP Partners Jeff Morton and Jeff Wolfson authored an article for Thomson Reuters a year removed from the United States Supreme Court issuing a unanimous decision on patent enablement in Amgen v. Sanofi. Read an excerpt below. A little over one year ago, in May 2023, the United States Supreme Court issued the unanimous decision on patent enablement in Amgen v. Sanofi (hereinafter referred to as the "Amgen" decision).
Morton in Life Science Leader: USPTO Proposed 'Terminal Disclaimer' Rule Could Impact Life Science Patent Protections
Haynes and Boone, LLP Partner Jeff Morton authored an article for Life Science Leader following a new proposal from the United States Patent and Trademark Office (USPTO) focusing on terminal disclaimer practice. Read an excerpt below. On May 10, 2024, the United States Patent and Trademark Office (USPTO) issued a notice of proposed rulemaking that focused on terminal disclaimer practice.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jeffrey
Contact Jeffrey, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack